Uncovering the Hidden Risks of Proton Pump Inhibitors: A Call for Caution in Long-Term Us
DOI:
https://doi.org/10.65761/pjcr.2024.1.1.12Keywords:
Proton pump inhibitors, long-term use, adverse effects, medication safety, risk assessmentAbstract
Therefore, an attempt was made to study a possible relation between proton pump inhibitors (PPIs) in continuing use and magnesium deficiency among the patients in a tertiary care hospital in Rawalpindi. We conducted a cross sectional study at Department of medicine Hayatabad medical complex Peshawar, Pakistan from January 2024 to July 2014. A total of 250 patients over the age of 18 years were enrolled into the study, all being on PPIs for at least one month. For that, we collect data on demographic factors, patient setting, body mass index, type and option of PPI and on suffering hypertension or diabetes mellitus. All participants underwent having their serum magnesium concentrations checked. The information was analyzed using SPSS. Of all, 51.5% (n=156) had hypomagnesemia. Furthermore, patients with the hypomagnesemia group were older on average (48.9 ± 12.3) than those with normal levels of magnesium (38.2 ± 11.4) (p<0.001). But multivariate logistic regression showed that duration > 6 months of PPI use (AOR: 58.1; 95% CI: 22.2-152.5; p < 0.001), diabetes mellitus (AOR: 23.1; 95% CI: 6.4- 82.6; p < 0.001) and hypertension (AOR: 3.2; 95% CI: 1.4-7.1; p < 0.001) were associated with low magnesium levels, while use of PPI did not significantly change Diabetes or hypertension and the long time use of PPI, along with advanced age were considered to be major risk factors. It explains the necessity for doctors to be conscious about the harm caused due to PPIs and to prescribe so carefully.
References
1. Dutta, A. K., Jain, A., Jearth, V., Mahajan, R., Panigrahi, M. K., Sharma, V., ... & Bhatia, S. (2023). Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship. Indian Journal of Gastroenterology, 42(5), 601-628.
2. Setia, A., Challa, R. R., Vallamkonda, B., Viswanadh, M. K., & Muthu, M. S. (2024). Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging. Nanotheranostics, 8(4), 535.
3. Lata, T., Trautman, J., Townend, P., & Wilson, R. B. (2023). Current management of gastro- oesophageal reflux disease—treatment costs, safety profile, and effectiveness: a narrative review. Gastroenterology report, 11, goad008.
4. Rückert-Eheberg, I. M., Nolde, M., Ahn, N., Tauscher, M., Gerlach, R., Güntner, F., ... & Baumeister, S. E. (2022). Who gets prescriptions for proton pump inhibitors and why? A drug- utilization study with claims data in Bavaria, Germany, 2010–2018. European journal of clinical pharmacology, 78(4), 657-667.
5. Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA clinical practice update on de-prescribing of
proton pump inhibitors: expert review. Gastroenterology, 162(4), 1334-1342.
6. Rossi, A., Perrella, L., Scotti, S., Olmastroni, E., Galimberti, F., Ardoino, I., ... & Casula, M. (2024). Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. Journal of Clinical Medicine, 13(20), 6283.
7. Awad, A., Al-Tunaib, A., & Al-Saraf, S. (2024). Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns. Frontiers in Pharmacology, 15, 1383698.
8. Maideen, N. M. P. (2023). Adverse effects associated with long-term use of proton pump inhibitors. Chonnam medical journal, 59(2), 115.
9. Iolascon, A., Andolfo, I., Russo, R., Sanchez, M., Busti, F., Swinkels, D., ... & from EHA-SWG Red Cell and Iron. (2024). Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. Hemasphere, 8(7), e108.
10. Sanam, S. (2024). Pharmacokinetic Drug Interactions of Multivitamins and Proton-pump Inhibitors (Doctoral dissertation, © University of Dhaka).
11. Choudhury, A., Jena, A., Jearth, V., Dutta, A. K., Makharia, G., Dutta, U., ... & Sharma, V. (2023). Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta- analysis. Expert review of gastroenterology & hepatology, 17(5), 479-487.
12. Di Bella, S., Sanson, G., Monticelli, J., Zerbato, V., Principe, L., Giuffrè, M., ... & Luzzati, R. (2024). Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clinical Microbiology Reviews, 37(2), e00135-23.
13. Gallo, A., Pellegrino, S., Pero, E., Agnitelli, M. C., Parlangeli, C., Landi, F., & Montalto, M. (2024). Main Disorders of Gastrointestinal Tract in Older People: An Overview. Gastrointestinal Disorders, 6(1), 313-336.
14. Kean, E. A., & Adeleke, O. A. (2024). Geriatric drug delivery―barriers, current technologies and the road ahead. Journal of Drug Targeting, 32(10), 1186-1206.
15. Szklarz, M., Gontarz-Nowak, K., Matuszewski, W., & Bandurska-Stankiewicz, E. (2022). Can Iron Play a Crucial Role in Maintaining Cardiovascular Health in the 21st Century?. International Journal of Environmental Research and Public Health, 19(19), 11990.
16. Morris, N., & Nighot, M. (2023). Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors. Bulletin of the National Research Centre, 47(1), 134.
17. Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology, 162(4), 1334-1342.
18. Holland, E., Matthews, K., Macdonald, S., Ashworth, M., Laidlaw, L., Cheung, K. S. Y., ... & Fraser, S. D. (2024). The impact of living with multiple long-term conditions (multimorbidity) on everyday life–a qualitative evidence synthesis. BMC Public Health, 24(1), 3446.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Clinical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
